《b受体阻滞剂（b receptor blocker）》由会员分享，可在线阅读，更多相关《b受体阻滞剂（b receptor blocker）（13页珍藏版）》请在金锄头文库上搜索。
1、b受体阻滞剂（B receptor blocker）1. can coronary artery intervention (PCI) be used after Betaloc?Answer: there is no special research to emphasize the use of Betaloc after PCI. But if patients receive PCI because of unstable angina or acute myocardial infarction, long-term treatment with betaloc is believe
2、d to be most beneficial.2. times Betaloc can be used as a first-line drug for angina pectoris?A: in October 2002, the revised ACC/AHA guidelines for the treatment of stable angina pectoris indicated that, without contraindications, beta blockers were the first choice for anti colic drugs.3. times wh
3、at Betaloc can be used for the treatment of arrhythmias?Answer: room early, room earlyAtrial fibrillation and atrial flutterSupraventricular tachycardiaMultifocal atrial tachycardiaQT extension syndromeArrhythmia caused by digitalis poisoningSudden cardiac death after myocardial infarction4., Chines
4、e are particularly sensitive to beta blockers, so is it unsafe for patients to use 25mg every day to use 100mg and 200mg?A: beta blockers vary in individual metabolism, and even in Western populations, the same dose can produce a difference of 20 times the serum concentration. But there is no large-
5、scale study showing racial differences, and CCS-2 research is being conducted in a large scale in the Chinese population. From the known safety data (27000 cases), 86% of the patients were well tolerated by oral 200mg betaloc.Can 5. times Betaloc be used in patients with cardiovascular disease assoc
6、iated with diabetes?Answer: the main body is B2 receptor to regulate blood sugar and Betaloc on the B1 receptor of B2 receptor is very small, so it can be used for patients with diabetes, and non selective B receptor blockers is not recommended. UKPDS studies and other large-scale pooled analyses ha
7、ve demonstrated that selective B1 blockers may benefit more patients at high risk.A multicenter cohort study assessed in patients with acute myocardial infarction beta blocker on diabetic survival effect (Kjekshus J, et al. European heart journal.1990; 11 (1): 43-50.). The results show that did not
8、receive beta blocker therapy in patients with a mortality rate of 1 years after hospital discharge was 23%. While the treatment group was only 10%. Multiple regression analysis showed that the use of beta blockers was an independent predictor of cardiovascular mortality in all patients with acute my
9、ocardial infarction with diabetes after 1 years of discharge.A subgroup of MERIT-HF of Betaloc sustained-release tablets on the efficacy and safety of diabetic patients with heart failure (Deedwania PC, et al. American heart journal. 2005; 149 (1): 159-167.). The results show that the use of metopro
10、lol sustained-release tablets in the treatment of the same can save the lives of patients and reduce the the risk of hospitalization for worsening heart failure. At the same time, metoprolol sustained release tablets are also well tolerated in patients with heart failure associated with type 2 diabe
11、tes mellitus. The incidence of hyperglycemia, hypoglycemia, and diabetic ulcers was similar in the two groups. The average dose used in diabetic patients with heart failure of metoprolol sustained-release tablets for 162mg without diabetes in patients with heart failure medication dose is 156mg, fur
12、ther explains the diabetic heart failure patients with application of metoprolol sustained-release tablets has good tolerance.Does 6. times Betaloc fail to treat patients with cardiovascular disease, diabetes or hyperlipidemia?Answer: the human body is mainly beta 2 receptor regulation of blood suga
13、r and blood lipid metabolism, Betaloc role in beta 1 receptor, beta 2 receptor function is very small, so it can be used in patients with diabetes or hyperlipidemia, rather than selective. UKPDS studies and other large-scale pooled analyses have shown that selective beta 1 receptor blockers offer mo
14、re benefit for high-risk patients.How many times does 7. times Betaloc apply to cardiovascular disease?Answer: hypertension, arrhythmia (including supraventricular and ventricular), heart failure, coronary heart disease (including myocardial infarction, angina), myocardial ischemia, migraine, hypert
15、rophic cardiomyopathy, mitral valve prolapse, dissecting aneurysm, digitalis poisoning, long QT syndrome and two tricuspid stenosis.What is the cause of sudden cardiac death by 8. times Betaloc?Answer: Betaloc is a lipophilic beta blocker, can inhibit lipid barrier through the brain beta 1 receptor,
16、 which increase vagal tone, sympathetic nerve tension is lowered, thereby reducing the incidence of ventricular fibrillation, reduce sudden cardiac death.Whats the significance of 9. times the lipophilicity of his music?Answer: lipophilic beta blockers are largely metabolized by liver metabolism, with a short half-life, no accumulation of kidney function, and safe use of renal insufficiency. Li
